Medically serious adverse effects of newer antidepressants.
Although safer than tricyclic antidepressants and monoamine oxidase inhibitors, the newer antidepressants may be associated with certain medically serious adverse effects, of which cardiovascular adverse effects, seizures, abnormal bleeding, hyponatremia, and agranulocytosis are discussed in this review. Data regarding the incidence and risk factors are summarized, and strategies for reducing the risk of these adverse effects and managing them are suggested. Identification of risk factors, appropriate antidepressant choice, and, when possible, careful monitoring may substantially reduce the incidence of these adverse effects and the morbidity associated with them.
Mago
Rajnish
R
Mood Disorders Program, Thomas Jefferson University, 833 South Chestnut Street, Philadelphia, PA 19107, USA. rajnish.mago@jefferson.edu
Mahajan
Rajeev
R
Thase
Michael E
ME
D000380:Agranulocytosis / Q000139:chemically induced*; D000928:Antidepressive Agents / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D003866:Depressive Disorder / Q000188:drug therapy*; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D007010:Hyponatremia / Q000139:chemically induced*; D008996:Monoamine Oxidase Inhibitors / Q000009:adverse effects*; D012640:Seizures / Q000139:chemically induced*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects*
D000928:Antidepressive Agents; D008996:Monoamine Oxidase Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors